Ribocyclob (Ribociclib)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antineoplastic agents - inhibitors of protein kinases

Included in the formulation
  • Kiskali
    pills inwards 
    Novartis Pharma AG     Switzerland
    • АТХ:

    L.01   Antineoplastic agents

    Pharmacodynamics:

    Selectively inhibits the cyclin-dependent kinases CDK 4 and 6, which stops the division of tumor cells during G1 phase, reduces the proliferation of cell lines in breast cancer. As a result, the tumor volume decreases.

    Pharmacokinetics:

    After oral administration, it is absorbed in the gastrointestinal tract. The maximum concentration in blood plasma is reached after 1-4 hours. The connection with plasma proteins is 70%.

    Metabolism in the liver.

    T ½ is 29-54 h. Elimination with feces (80%) and kidneys (20%).

    Indications:

    It is used as part of complex therapy with an aromatase inhibitor for the treatment of postmenopausal women with HER2-negative and positive hormone-receptor (HR) growth factor. Used for progressive or metastatic breast cancer.

    ICD-10

    II.C50   Malignant neoplasm of breast)

    Contraindications:

    Severe hepatic insufficiency, age under 18, pregnancy and lactation, individual intolerance.

    Carefully:

    Dysfunction of the liver of moderate or severe degree, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside, regardless of meal time, 600 mg 1 time / day for 21 days, followed by a break in 7 days.

    The highest daily dose: 600 mg.

    The highest single dose: 600 mg.

    Side effects:

    Central and peripheral nervous system: fast fatiguability, peripheral neuropathy.

    Respiratory system: pneumonitis - interstitial pulmonary process, dyspnea, rarely - pulmonary embolism.

    Hemopoietic system: neutropenia, leukopenia, thrombocytopenia, anemia.

    The cardiovascular system: palpitations, heart failure, nosebleeds.

    Digestive system: stomatitis, anorexia, diarrhea, nausea, vomiting.

    Dermatological reactions: acne, alopecia, rash.

    Allergic reactions.

    Overdose:

    Acute left ventricular failure.

    Treatment is symptomatic.

    Interaction:

    When used simultaneously with inducers CYP3A4 (carbamazepine, rifampicin, phenytoin), careful monitoring of the patient's condition is recommended to prevent unwanted side reactions.

    Special instructions:

    Monitoring of the blood count, including coagulograms, every 2 weeks during the first 2 months of treatment, then monthly and according to clinical indications.

    If you miss a dose, it is recommended that you take the next dose as soon as possible. The administration of a double dose is once contraindicated.

    It is not recommended to drink the drug with grapefruit juice.

    During treatment, patients need to use reliable contraceptive methods. If the drug is dizzy, you should stop driving the car and work with moving mechanisms.

    Instructions
    Up